Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

The Steps Drug Makers Must Take Now To Avoid A Post-COVID-19 Manufacturing Crisis

Executive Summary

How pharmaceutical companies should plan to catch up after the pandemic and explain what happened to inspectors.

You may also be interested in...



FDA Prioritizes Shortages Post-Pandemic

Guidance from the FDA urges a focus on restarting production, easing drug shortages and completing quality assurance activities for quarantined batches when the coronavirus pandemic recedes.

US FDA On Resuming Normal Manufacturing Operations When Pandemic Recedes

Focus on restarting production, easing drug shortages and completing quality assurance activities for quarantined batches, agency guidance says.

Responding To FDA 483s And Warning Letters: Some Dos, Don’ts And Red Flags

Invalidated OOS results are ‘red flags’ during FDA inspections and ‘denying, delaying, limiting or refusing’ a drug inspection proposed by the agency could have serious consequence, participants at a recent webinar on best practices for responding to Form 483s and warnings letters heard.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS142254

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel